Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

UBS Maintains Buy on DexCom, Raises Price Target to $163

Author: Benzinga Newsdesk | April 10, 2024 11:22am
UBS analyst Danielle Antalffy maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $153 to $163.

Posted In: DXCM

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist